Bristol-Myers Squibb (BMY) Tops Q2 EPS by 15c, Updates FY EPS Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.63, $0.15 better than the analyst estimate of $1.48. Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.97 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2020 EPS of $6.10-$6.25, versus the consensus of $6.20. Bristol-Myers Squibb sees FY2020 revenue of $40.5-42 billion, versus the consensus of $41.9 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance